Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Cristofanilli on the Need for Biosimilars in Oncology

December 16th 2019

Massimo Cristofanilli, MD, discusses the need for biosimilars in oncology.

Dr. Pagel on Biosimilars and Cost Consciousness in Oncology

December 13th 2019

John M. Pagel, MD, PhD, discusses the use of biosimilars in oncology and the importance of cost consciousness.

Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian Cancer

December 11th 2019

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

December 10th 2019

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. McBride on the Potential of Biosimilars in Oncology

December 5th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.

Dr. Vidal on Choosing Between Available Trastuzumab Biosimilars

December 4th 2019

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Trastuzumab Biosimilar Ogivri Launches in United States

December 3rd 2019

The trastuzumab biosimilar Ogivri (MYL-1401O; trastuzumab-dkst) has been launched in the United States for all indications of the reference product, including the treatment of patients with HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma.

Dr. McBride on the Regulatory Pathway for Biosimilars in Oncology

December 3rd 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator, Hematology/Oncology, The University of Arizona Cancer Center, clinical assistant professor, The University of Arizona College of Pharmacy, discusses the regulatory pathway for biosimilars in oncology.

Explaining the Variability of Biologics and Biosimilars

December 2nd 2019

Jim M. Koeller, MS, FHOPA, discusses the inherent variability of recombinant DNA technology behind biosimilars.

Dr. McBride on the Emergence of Biosimilars in Oncology

November 27th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.

Chinese Trastuzumab Biosimilar Demonstrates Equivalency in HER2+ Breast Cancer

November 25th 2019

The Chinese-manufactured trastuzumab biosimilar HLX02 demonstrated similar objective response rates to the reference product at 24 weeks in patients with treatment-naïve or recurrent metastatic HER2-positive breast cancer.

Dr. Somer on the Expansion of Biosimilars in Oncology

November 22nd 2019

Bradley G. Somer, MD, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.

Can Biosimilars Help Control Rising Drug Costs?

November 22nd 2019

Lee S. Schwartzberg, MD, FACP, discusses the development and approval process for biosimilars and explains how their availability could drive down out-of-pocket costs for patients.

Dr. Somer on Education for Biosimilars

November 21st 2019

Bradley G. Somer, MD, discusses the education surrounding biosimilars in oncology.

Dr. Robson on Differences Between Biosimilars and Biologics in Oncology

November 20th 2019

Mark E. Robson, MD, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.

FDA Accepts Application for Bevacizumab Biosimilar

November 19th 2019

The FDA has accepted a biologics license application for the proposed bevacizumab biosimilar SB8.

Emergence of Biosimilars Poised to Alleviate Financial Toxicity in Oncology

November 16th 2019

Bradley G. Somer, MD, discusses the emergence of biosimilars in oncology

Dr. Tauer on the Potential Implications of Biosimilars on Cancer Research Funding

November 16th 2019

Kurt W. Tauer, MD, FACP, discusses the potential implications of biosimilars on cancer research funding.

Dr. Somer on Hesitancy Regarding Biosimilar Use in Oncology

November 15th 2019

Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, explains where the hesitancy regarding biosimilar use in oncology.

Dr. Schwartzberg on Increasing Competition With Biosimilars in Oncology

November 14th 2019

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.